Publications
Berg van der P, Gao W, Ahsman M.J, Arrington L, Kesisoglou F, Miller R, Post T.M, Rizk M.L. Understanding effect site pharmacology of uprifosbuvir, a hepatitis C virus nucleoside inhibitor: Case study of a multidisciplinary modeling approach in drug development. CPT Pharmacometrics Syst Pharmacol. 2021 May 2. doi: 10.1002/psp4.12644. Epub ahead of print. PMID: 33934558.…
Bukkems V. E., Post T. M., Colbers A. P., Burger D. M., Svensson E. M. A population pharmacokinetics analysis assessing the exposure of raltegravir once‐daily 1200mg in pregnant women living with HIV. CPT Pharmacometrics Syst. Pharmacol.(December 2020): 1–12, 2020. [Link to publication]
Solms A., Shah A., Berntorp E., Tiede A., Iorio A., Linardi C., Ahsman M., Mancuso M. E., Zhivkov T., Lissitchkov T. Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. Ann. Hematol. 99(11): 2689–2698, 2020 [Link to publication].
Snelder N., Heinig R., Drenth H.J., Joseph A., Kolkhof P., Lippert J., Garmann D., Ploeger B., Eissing T. Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease. Clin Pharmacokinet. 359-370 :2020. [Link to publication]
Biselele T., Bambi J., Betukumesu D. M., Ndiyo Y., Tabu G., Kapinga J., Bola V, Makaya P., Tjabbes H., Vis P., Peeters-Scholte C.. A Phase IIa Clinical Trial of 2 ‑ Iminobiotin for the Treatment of Birth Asphyxia in DR Congo , a Low ‑ Income Country. Pediatr. Drugs: 2020. [Link to publication]
Kogame A., Ishikawa K., DeJongh J., Tagawa Y., Matsui H., Moriya Y., Kondo T., Asahi S. Pharmacokinetic and pharmacodynamic modeling of the metastin/kisspeptin analog, TAK-448, for its anti-tumor efficacy in a rat xenograft model. Biopharm. Drug Dispos.: 2020. [Link to publication]
Hoefman S., Snelder N., van Noort M., Garcia-Hernandez A., Onkels H., Larsson T.E., Bergmann K.R. Mechanism-based modeling of the effect of a novel inhibitor of vascular adhesion protein-1 on albuminuria and renal function markers in patients with diabetic kidney disease. J Pharmacokinet Pharmacodyn. 2020 [Link to publication]
Snelder N., Hoefman S., Garcia-Hernandez A., Onkels H., Larsson T.E., Bergmann K.R. Population pharmacokinetics and pharmacodynamics of a novel vascular adhesion protein-1 inhibitor using a multiple-target mediated drug disposition model. J Pharmacokinet Pharmacodyn. 2020 [Link to publication]
Keunecke A., Hoefman S., Drenth H.J., Zisowsky J., Cleton A., Ploeger B.A. Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intake. Br. J. Clin. Pharmacol.(December 2019): 1–15, 2020 [Link to publication]
Favie L. M. A., Peeters-Scholte C. M. P. C. D., Bakker A., Tjabbes H., Egberts T. C. G., van Bel F., Rademaker C. M. A., Vis P., Groenendaal F. Pharmacokinetics and short-term safety of the selective NOS inhibitor 2-iminobiotin in asphyxiated neonates treated with therapeutic hypothermia. Pediatr. Res.: 2019. [Link to publication]